表紙：胃不全麻痺治療薬の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別、2025～2032年産業予測

市場調査レポート

商品コード

1755468

胃不全麻痺治療薬の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別、2025～2032年産業予測

Gastroparesis Drugs Market Size, Share, and Growth Analysis, By Type (Branded, Generics), By Drug Class (Amino salicylates, Digestive enzymes), By Route of Administration, By Application, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年06月16日
発行: SkyQuest
ページ情報: 英文 192 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 771,574円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 902,596円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,033,618円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.58円

全表示
概要
目次

概要

サンプル依頼リストに入れる

胃不全麻痺治療薬の世界市場規模は2023年に57億米ドルと評価され、2024年の60億1,000万米ドルから2032年には92億3,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは5.5％で成長する展望です。

胃不全麻痺治療薬市場は、胃不全麻痺の主要因である糖尿病の有病率の上昇と、胃腸疾患に対する意識の高まりに大きく後押しされ、安定した成長が見込まれています。吐き気、腹部膨満感、胃排出遅延を管理するための効果的なソリューションとしてプロトンポンプ阻害剤やプロキネティック製剤が台頭しており、非侵襲的で症状に焦点を当てた治療法に対する需要は増加の一途をたどっています。糖尿病関連合併症が増加する中、糖尿病性胃不全麻痺が適応症の大半を占めていることは注目に値します。小売薬局が主要な流通チャネルであることに変わりはないが、オンライン薬局がその利便性から支持を集めています。競合情勢では、大手製薬企業が研究開発や戦略的提携に投資し、進化する患者ニーズに対応しています。北米は強力なヘルスケアシステムと先進的な治療法に支えられて市場をリードしており、欧州（特にドイツと英国）も患者ケアの著しい進歩を示しています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他の欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主要市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）
  主要企業プロファイル
  - AbbVie Inc.（米国）
  - Evoke Pharma, Inc.（米国）
  - Vanda Pharmaceuticals Inc.（米国）
  - Takeda Pharmaceutical Company Limited（日本）
  - AstraZeneca PLC（英国）
  - GlaxoSmithKline PLC（GSK）（英国）
  - Neurogastrx Inc.（米国）
  - Processa Pharmaceuticals, Inc.（米国）
  - Abbott Laboratories（米国）
  - Bausch Health Companies Inc.（カナダ）
  - Rhythm Pharmaceuticals, Inc.（米国）
  - CinDome Pharma（米国）
  - ANI Pharmaceuticals, Inc.（米国）
  - Johnson & Johnson Inc.（米国）
  - Pfizer Inc.（米国）
  - Teva Pharmaceutical Industries Ltd.（イスラエル）
  - Medtronic PLC（アイルランド）
  - Otsuka Pharmaceutical Co. Ltd.（日本）
  - Theravance Biopharma, Inc.（米国）
  - Cadila Pharmaceuticals（インド）

結論と提言

Product Code: SQMIG35I2378

Global Gastroparesis Drugs Market size was valued at USD 5.7 billion in 2023 and is poised to grow from USD 6.01 billion in 2024 to USD 9.23 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The gastroparesis drugs market is poised for steady growth, largely propelled by the rising prevalence of diabetes, a leading factor behind gastroparesis, coupled with heightened awareness of gastrointestinal disorders. The demand for non-invasive, symptom-focused therapies continues to rise, with proton pump inhibitors and prokinetic agents emerging as effective solutions for managing nausea, bloating, and delayed gastric emptying. Notably, diabetic gastroparesis dominates the indication segment amid increasing diabetes-related complications. Retail pharmacies remain the primary distribution channel, yet online pharmacies are gaining traction for their convenience. The competitive landscape features major pharmaceutical companies investing in R&D and strategic partnerships to address evolving patient needs. North America leads the market, supported by strong healthcare systems and advanced treatments, while Europe, particularly Germany and the UK, also showcases significant advancements in patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroparesis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroparesis Drugs Market Segments Analysis

Global Gastroparesis Drugs Market is segmented by Type, Drug Class, Route of Administration, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generics. Based on Drug Class, the market is segmented into Amino salicylates, Digestive enzymes, Proton Pump Inhibitors, Laxatives, Anti-Emetics, H2 Antagonists, Anti-Diarrheal, Biologics/Biosimilar and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on Application, the market is segmented into Crohn's disease, Ulcerative colitis, GERD, IBS and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroparesis Drugs Market

A significant factor propelling the Global Gastroparesis Drugs market is the increasing prevalence of diabetes, which has a strong association with the condition of gastroparesis. As the number of individuals diagnosed with Type 1 and Type 2 diabetes rises worldwide, the occurrence of related complications, such as diabetic gastroparesis, is becoming more pronounced, thus creating a heightened demand for effective medical treatments. A report from the International Diabetes Federation in January 2024 highlighted a surge in diabetes cases globally, particularly in regions like Asia and North America. This trend has prompted pharmaceutical companies, including Evoke Pharma, to enhance the production of medications like Gimoti, focusing specifically on addressing diabetic gastroparesis.

Restraints in the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market faces significant challenges due to the limitations of currently available treatments, which primarily provide symptomatic relief while often causing undesirable side effects that discourage long-term use and diminish overall patient satisfaction. Additionally, regulatory obstacles persist, as evidenced by the FDA's April 2024 decision to reject the approval of a new prokinetic agent from PharmaNova, citing insufficient long-term safety data. This situation highlights the complexities involved in developing new and effective therapies, underscoring the difficulties that pharmaceutical companies encounter in navigating the regulatory landscape to bring safe and innovative treatments to market.

Market Trends of the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market is undergoing a significant transformation, driven by the integration of artificial intelligence in drug discovery and clinical trial design. As pharmaceuticals grapple with the complexities of tailoring treatments for this multifaceted disorder, AI technologies are revolutionizing R&D processes. Recent collaborations, such as Quris-AI's partnership with NeuroGasTx, exemplify this trend, demonstrating how AI can enhance patient simulations and optimize trial efficiency. Such innovations have led to a 25% increase in enrollment rates and reduced costs, thereby accelerating the development timeline for new therapies. This shift towards AI-driven methodologies is expected to enhance treatment efficacy and patient outcomes in the gastroparesis market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Gastroparesis Drugs Market Size by Type & CAGR (2025-2032)

Market Overview
Branded
Generics

Global Gastroparesis Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Amino salicylates
Digestive enzymes
Proton Pump Inhibitors
Laxatives
Anti-Emetics
H2 Antagonists
Anti-Diarrheal
Biologics/Biosimilar
Others

Global Gastroparesis Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable
Others

Global Gastroparesis Drugs Market Size by Application & CAGR (2025-2032)

Market Overview
Crohn's disease
Ulcerative colitis
GERD
IBS
Others

Global Gastroparesis Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Gastroparesis Drugs Market Size & CAGR (2025-2032)

North America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- US
- Canada
Europe (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Route of Administration, Application, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evoke Pharma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vanda Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline PLC (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurogastrx Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Processa Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rhythm Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CinDome Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ANI Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cadila Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

胃不全麻痺治療薬の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、投与経路別、用途別、流通チャネル別、地域別、2025～2032年産業予測

Gastroparesis Drugs Market Size, Share, and Growth Analysis, By Type (Branded, Generics), By Drug Class (Amino salicylates, Digestive enzymes), By Route of Administration, By Application, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と展望

主要市場の考察

胃不全麻痺治療薬市場規模：タイプ別&CAGR（2025～2032年）

胃不全麻痺治療薬市場規模：薬剤クラス別&CAGR（2025～2032年）

胃不全麻痺治療薬市場規模：投与経路別&CAGR（2025～2032年）

胃不全麻痺治療薬市場規模：用途別&CAGR（2025～2032年）

胃不全麻痺治療薬市場規模：流通チャネル別&CAGR（2025～2032年）

胃不全麻痺治療薬市場規模&CAGR（2025～2032年）